Study to Determine the Difference in Reduction of Bioaerosols in a Long-term Care Facility
Launched by C-POLAR INNOVATIONS · Jul 17, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of air filters in a long-term care facility can affect air quality. Specifically, the trial will compare standard air filters with a special type called C-POLAR filters, which are designed to improve air quality by reducing harmful particles in the air, known as bioaerosols. Throughout the study, air quality will be continuously monitored using special devices that measure various factors, such as tiny particles, carbon dioxide, and temperature.
Everyone who enters the long-term care facility, including residents, staff, and visitors, will be part of the study since the new filters will be installed throughout the building. There’s no need for individuals to give special permission to participate. However, anyone who prefers not to enter the facility until the study is complete will not be included. Participants can expect to see improvements in the air quality during the study, but it’s important to note that the research involves minimal risk and the outcome may vary.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Any resident, staff, and any individual who enters the long term care facility will be in a broad sense, involved in this study, as the MERV 13 HVAC filters will be installed within the HVAC system and will not allow anyone to not participate in the study who enters the facility. It is impracticable to carry out this research of comparing two different HVAC filters in an active long term care setting by receiving prior consent from all individuals who may enter, such as vendors or visitors. This research involves no more than minimal risk and may or may not improve air quality or minimize bioaerosols in the facility.
- Exclusion Criteria:
- • 1. Does not wish to enter the long-term care facility until completion of study.
About C Polar Innovations
C-Polar Innovations is a forward-thinking clinical trial sponsor dedicated to advancing medical research through innovative solutions and strategic partnerships. With a focus on optimizing clinical trial design and execution, C-Polar Innovations leverages cutting-edge technology and a patient-centric approach to enhance the efficiency and effectiveness of clinical studies. Committed to driving scientific progress and improving patient outcomes, the organization collaborates with a diverse range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers, to bring transformative therapies to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kelowna, British Columbia, Canada
Patients applied
Trial Officials
Deanne Taylor, PhD
Principal Investigator
Kelowna General Hospital
Michael Mansour, MD, PhD
Principal Investigator
Harvard Medical School (HMS and HSDM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported